Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2000040000Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Pathological complete response rate. Started Dec 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000040000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040000.